Leann Bassing, MD
Rheumatology · Yankton, SDNPI 1871784124
Payments from drug & device makers
What this record shows
3 manufacturers reported payments, led by Genentech USA, Inc. at 52.9% of the total. Reporting peaked in 2019 at $100 and has fallen 82.1% since, to $18 in 2025.
Across 5 payments — averaging $37.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$100
- Amgen$63
- Boehringer Ingelheim$26
What the payments were for
- Food & beverage$8947%
- Education$10053%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 1 | $100 |
| Amgen(2 entities) | 3 | $63 |
| Boehringer Ingelheim | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few rheumatology providers in South Dakotato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 30 | $204,740 |
| Orencia ClickjectAbatacept | 24 | $133,475 |
| Cyltezo(Cf) PenAdalimumab-Adbm | 20 | $122,136 |
| Actemra ActpenTocilizumab | 15 | $81,789 |
| Hydroxychloroquine Sulfate | 510 | $24,400 |
| MethotrexateMethotrexate Sodium | 475 | $18,151 |
| Mycophenolate Mofetil | 22 | $5,007 |
| Leflunomide | 56 | $3,999 |
| Sulfasalazine | 106 | $3,786 |
| Allopurinol | 358 | $3,172 |
| Duloxetine Hcl | 63 | $1,397 |
| Gabapentin | 21 | $946 |
| Prednisone | 193 | $886 |
| Azathioprine | 12 | $714 |
| Minocycline Hcl | 12 | $395 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Yankton
- Kelsey HolkesvikSioux Falls$5K
- Jenna King-SonaSioux Falls$4K
- Jessica SrstkaSioux Falls$3K
- Kara PetersenSioux Falls$3K
- Kelly Delaney-NelsonDakota Dunes$3K
- Mark VercelSioux Falls$2K
- Brian BowersRapid City$2K
- Wais AfzalSioux Falls$1K
- Vivek JosephSioux Falls$698
- Gregory MummSioux Falls$599
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.